Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.

Phase II study of amonafide in advanced breast cancer.

III clinical trial design.

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

III Non-Small Cell Lung Cancer.

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.

Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.

Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer.

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Phase II trial of N-methylformamide in lung cancer.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

IV Non-Small Cell Lung Cancer.

RAS status in Korean patients with stage III and IV colorectal cancer.

Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.

Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer.

IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.

[Monochemotherapeutic treatment of advanced stage III and IV ovarian cancer].

Suggest Documents

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer.

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.

Phase II study of amonafide in advanced breast cancer.

III clinical trial design.

Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.

III Non-Small Cell Lung Cancer.

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.

Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.

Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer.

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Phase II trial of N-methylformamide in lung cancer.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

IV Non-Small Cell Lung Cancer.

RAS status in Korean patients with stage III and IV colorectal cancer.

Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.

Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer.

IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.

[Monochemotherapeutic treatment of advanced stage III and IV ovarian cancer].

Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.

Recommend Documents

Follow Us